Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting
April 13 2020 - 7:00AM
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company
leveraging its proprietary DNAbilize® liposomal delivery and
antisense technology to develop a portfolio of targeted nucleic
acid cancer drugs, today announced an upcoming virtual poster
presentation at the 2020 American Association for Cancer
Research (AACR) Annual Meeting, taking place from April 27-28,
2020.
Dr. Ana Tari Ashizawa, Senior Vice President of
Research, Development and Clinical Design, at Bio-Path Holdings
will summarize the Phase 1 study design of BP1002 (liposomal Bcl-2
antisense), the Company’s second drug candidate, for the treatment
of lymphomas and chronic lymphocytic leukemia.
Details for the virtual poster presentation are as follows:
Date: Monday, April 27, 2020Poster
Release Time: 12:01 am Eastern
TimeSession: Phase I Trials In
ProgressAbstract: 9464Title: “A
Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and
Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients
with Advanced Lymphoid Malignancies”
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing
DNAbilize®, a novel technology that has yielded a pipeline of RNAi
nanoparticle drugs that can be administered with a simple
intravenous transfusion. Bio-Path’s lead product candidate,
prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2
study for the treatment of blood cancers and has filed an IND for a
Phase 1 clinical trial for solid tumors. The Company’s second
pipeline candidate is BP1002, which targets the Bcl-2 protein and
is planned to be evaluated for the treatment of lymphoma and
chronic lymphocytic leukemia. In addition, an IND application for
BP1003, a novel liposome-incorporated STAT3 antisense
oligodeoxynucleotide developed by Bio-Path as a specific inhibitor
of STAT3, is expected to be filed in 2020.
For more information, please visit the Company's
website athttp://www.biopathholdings.com.
Contact Information:
Investors
Will O’ConnorStern Investor Relations,
Inc.212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path
Holdings, Inc. 832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Sep 2023 to Sep 2024